Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.59M | $10.4M | $219M | $35.2M | $155M | $470M | $113M | $90.2M | $83.3M | $170M |
| Revenue growth | — | 126.5% | 2002.4% | -83.9% | 338.7% | 204.3% | -76.0% | -19.9% | -7.7% | 104.5% |
| Operating income | -$65.3M | -$75.9M | $88.1M | -$149M | -$119M | $160M | -$263M | -$268M | -$233M | -$161M |
| Operating margin | -1423.8% | -730.2% | 40.3% | -422.9% | -77.1% | 34.0% | -233.2% | -297.1% | -280.0% | -94.6% |
| Net income | -$63.0M | -$73.2M | $99.9M | -$94.7M | -$111M | $128M | -$280M | -$263M | -$227M | -$194M |
| Net margin | -1372.1% | -704.0% | 45.7% | -268.9% | -72.0% | 27.2% | -248.7% | -292.0% | -272.5% | -113.8% |
| EPS (diluted) | -$2.38 | -$2.45 | $2.73 | -$2.58 | -$2.98 | $2.91 | -$6.50 | -$6.02 | -$4.59 | -$3.76 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$48.6M | -$58.0M | $105M | -$108M | -$54.1M | $219M | -$207M | -$218M | -$173M | -$124M |
| Capital expenditures | $8.15M | $7.16M | $13.3M | $11.7M | $26.9M | $84.2M | $30.7M | $9.96M | $2.44M | $2.41M |
| Free cash flow | -$56.7M | -$65.2M | $91.4M | -$119M | -$80.9M | $135M | -$238M | -$228M | -$176M | -$126M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $24.8M | $46.7M | $75.6M | $69.5M | $338M | $345M | $97.0M | $34.5M | $57.5M | $34.5M |
| Total assets | $173M | $199M | $544M | $498M | $708M | $1.11B | $833M | $574M | $466M | $453M |
| Total liabilities | $11.0M | $15.6M | $35.0M | $47.7M | $330M | $350M | $317M | $262M | $206M | $350M |
| Shareholders' equity | $162M | $183M | $509M | $450M | $378M | $764M | $516M | $312M | $260M | $103M |
| Retained earnings | -$115M | -$188M | -$83.0M | -$178M | -$289M | -$161M | -$442M | -$705M | -$932M | -$1.13B |
| Shares (wtd avg diluted) | 26.4M | 29.9M | 36.6M | 36.7M | 37.3M | 43.9M | 43.2M | 43.7M | 49.5M | 51.6M |
Every figure is extracted from REGENXBIO Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.